{"nctId":"NCT01736865","briefTitle":"Vitamin D for Established Type 2 Diabetes (DDM2)","startDateStruct":{"date":"2012-12"},"conditions":["Type 2 Diabetes"],"count":127,"armGroups":[{"label":"placebo","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"cholecalciferol","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Cholecalciferol"]}],"interventions":[{"name":"Cholecalciferol","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Established type 2 diabetes, defined by one of the following two criteria:\n* Age ≥ 25 years and ≤ 75 years\n* BMI: 23 to 40 kg/m2 inclusive\n* Provision of signed and dated written informed consent prior to any study procedures.\n\nMajor Exclusion Criteria\n\n* \"Severe\" diabetes defined by one of the following criteria:\n* \\- (a) Symptoms of hyperglycemia;\n* \\- (b) Screening HbA1c ≥ 7.5 \\[may indicate potential for rapid progression during the trial necessitating need to amplify diabetes-specific pharmacotherapy\\]\n* History of nephrolithiasis or hypercalcemia","healthyVolunteers":false,"sex":"ALL","minimumAge":"25 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Disposition Index","description":"Disposition index by the insulin secretion sensitivity index-2 (ISSI-2). This is an calculated value which represents the ability of a person's pancreatic beta cells to lower blood glucose. A higher number means the pancreas is better able to secrete insulin and improve glucose levels.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.023","spread":"0.057"},{"groupId":"OG001","value":"0.149","spread":"0.056"}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Change in Glycemia","description":"Change in glycemia (categorical variable, composite outcome) defined as \\[1\\] a decrease in diabetes medications or \\[2\\] a reduction of equal to or more than 0.4 HbA1c units from baseline without increasing medications.","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"53","spread":null},{"groupId":"OG001","value":"52","spread":null}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Hemoglobin A1c","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.2","spread":"0.07"},{"groupId":"OG001","value":"0.2","spread":"0.06"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Change in Diabetes Medications","description":null,"classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Variability of Response to Vitamin D Supplementation in Subgroups.","description":"Variability of response to vitamin D supplementation in subgroups defined by baseline characteristics: (1) race; (3) 25OHD concentration; (3) diabetes treatment.","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Effect of Vitamin D Supplementation on Blood 25-hydroxyvitaminD Concentration","description":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"27.5","spread":"12.0"},{"groupId":"OG001","value":"25.8","spread":"10.3"}]}]}]},{"type":"OTHER_PRE_SPECIFIED","title":"Cardiovascular Risk Factors","description":"Cardiovascular risk factors defined as blood pressure, lipid profile, C-reactive protein and urine albumin excretion","classes":[]},{"type":"OTHER_PRE_SPECIFIED","title":"Effect of Vitamin D Supplementation on Plasma Concentrations of Surrogate Biomarkers of Cholesterol Absorption (Campesterol and β-sitosterol) and Endogenous Synthesis (Lathosterol and Desmosterol)","description":null,"classes":[]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":6,"n":61},"commonTop":["Adverse Event"]}}}